Approval · Notice of Compliance 12027 · 2011
TEVA-RANITIDINE: Notice of Compliance 12027
Issued January 24, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12027
- Date
- January 24, 2011
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- Histamine H2-receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-RANITIDINE | 00828564 | Cancelled Post Market |
| TEVA-RANITIDINE | 00828556 | Cancelled Post Market |
| TEVA-RANITIDINE SOLUTION | 02242940 | Cancelled Post Market |
| TEVA-RANITIDINE INJECTION | 02231487 | Cancelled Pre Market |
Medicinal ingredients
- RANITIDINE HCL 150 MG per TAB
- RANITIDINE HCL 300 MG per TAB
- RANITIDINE HCL 15 MG per ML
- RANITIDINE HCL 25 MG per ML